• Pazopanib Hydrochloride: Optimizing Oncology Research Workfl

  2026-07-02

  Pazopanib Hydrochloride (GW786034) empowers researchers with robust, multi-target inhibition for advanced cancer model systems. This article delivers actionable workflow enhancements, troubleshooting guidance, and practical metrics—grounded in recent methodological breakthroughs—to maximize the reliability and translational relevance of anti-angiogenic studies.

• CUDC-907: Protocol and QC Guidance for Dual PI3K/HDAC Inhibi

  2026-07-01

  CUDC-907 addresses the need for precise, dual inhibition of PI3K and HDAC pathways in cell-based cancer research models. It is optimized for in vitro workflows investigating cell signaling, cell cycle arrest, and apoptosis, but is not intended for diagnostic or clinical applications.

• 3-Deazaneplanocin (DZNep): Epigenetic Modulation and Assay I

  2026-07-01

  Explore the advanced mechanisms and practical applications of 3-Deazaneplanocin (DZNep) as an epigenetic modulator in cancer research. This article uniquely bridges molecular action with assay design, providing in-depth guidance for experimentalists.

• Ciprofloxacin in Antimicrobial Resistance Research Workflows

  2026-06-30

  Ciprofloxacin stands out as a premier fluoroquinolone antibiotic for modeling bacterial resistance and evaluating DNA replication inhibition in the lab. This article translates cutting-edge reference findings and experimental best practices into actionable protocols, troubleshooting guidance, and advanced applications using high-purity Ciprofloxacin from APExBIO.

• EdU Imaging Kits (Cy5): Precision S-Phase DNA Synthesis Dete

  2026-06-30

  EdU Imaging Kits (Cy5) deliver unparalleled sensitivity for quantifying cell proliferation by targeting S-phase DNA synthesis, outclassing traditional BrdU methods. Their click chemistry workflow preserves morphology and antigenicity, enabling robust fluorescence microscopy and flow cytometry applications across cancer biology, genotoxicity, and pharmacodynamics.

• Partial β-Secretase Inhibition Preserves Synaptic Function i

  2026-06-29

  Satir et al. (2020) reveal that partial inhibition of β-secretase can lower amyloid β (Aβ) production by up to 50% without impairing synaptic transmission in neuron cultures. These findings refine our understanding of therapeutic strategies for Alzheimer’s disease and highlight the importance of dosing in targeting amyloidogenic pathways.

• DiscoveryProbe FDA-approved Drug Library: Optimizing HTS Wor

  2026-06-29

  The DiscoveryProbe FDA-approved Drug Library unlocks streamlined, reproducible high-throughput screening with clinically validated compounds in ready-to-use formats. This resource empowers drug repositioning, pharmacological target identification, and translational research, especially for challenging areas like pain, cancer, and neurodegeneration.

• Qushi Huoxue Ointment Modulates Autophagy and Ferroptosis in

  2026-06-28

  Liu et al. provide detailed mechanistic evidence that Qushi Huoxue ointment (QSHXO) ameliorates metabolic associated steatotic liver disease (MASLD) in mice by activating autophagy and inhibiting ferroptosis. This dual regulation offers new insight into potential therapeutic strategies and experimental targets in MASLD research.

• BIIE 0246: Precision Neuropeptide Y Y2 Receptor Antagonism i

  2026-06-27

  BIIE 0246 empowers researchers to dissect the nuanced roles of neuropeptide Y Y2 receptor signaling across neuroscience and cardiometabolic models. This guide translates cutting-edge findings and hands-on workflows into actionable protocols, comparative insights, and troubleshooting strategies for robust, reproducible results.

• Trolox in Organoid and Oxidative Injury Research: Protocols

  2026-06-26

  Trolox, a water-soluble vitamin E analogue, is redefining antioxidant and organoid workflows by enabling robust modeling of oxidative stress and precise assay calibration. Discover how its unique properties and APExBIO quality empower high-efficiency pancreatic organoid generation, advanced neurodegeneration models, and reproducible high-throughput screening.

• AI-Driven Discovery of Senolytics: Machine Learning Unveils

  2026-06-26

  The referenced study introduces a cost-effective machine learning pipeline that identifies novel senolytic compounds from heterogeneous published datasets. This approach significantly reduces drug screening costs and has practical implications for age-related disease and cancer research, emphasizing the potential of computational tools in early-stage drug discovery.

• Targeting the c-Myc/TERT/NFκB Axis: 10074-G5 in Translationa

  2026-06-25

  This article explores the mechanistic and translational potential of 10074-G5, a small-molecule c-Myc inhibitor from APExBIO, in disrupting the oncogenic c-Myc/TERT/NFκB axis. Drawing from recent evidence on microRNA-driven cancer aggressiveness and advanced protocol strategies, the discussion offers actionable insights for translational researchers seeking to harness targeted inhibitors for apoptosis, cell cycle arrest, and tumor regression studies. The narrative bridges molecular rationale, experimental design, and strategic deployment, positioning 10074-G5 as a next-generation tool for cancer research.

• Caffeic Acid Phenethyl Ester (CAPE): Decoding NF-κB Inhibiti

  2026-06-25

  Explore how Caffeic Acid Phenethyl Ester (CAPE) uniquely inhibits NF-κB and modulates tumor angiogenesis, with mechanistic insights and advanced protocol guidance. This article bridges molecular detail with translational research, offering a deeper perspective on CAPE’s role in oncology and neuroinflammation.

• DRD4 Drives Chemo-Resistance via PI3K/Akt/β-Catenin in Liver

  2026-06-24

  This study demonstrates that dopamine receptor D4 (DRD4) enhances chemo-resistance and cancer stem cell-like properties in hepatocellular carcinoma by activating the PI3K/Akt/β-catenin signaling axis. These findings highlight DRD4 as a targetable driver of liver cancer stemness and recurrence, providing mechanistic insight for future therapy design.

• Ziprasidone HCl in Tumor Metabolism and Neuro Research Workf

  2026-06-23

  Ziprasidone Hydrochloride (Ziprasidone HCl) uniquely bridges neuroscience and cancer research as both a potent serotonin/dopamine receptor antagonist and non-competitive GOT1 inhibitor. This guide details evidence-based protocols, troubleshooting strategies, and the latest translational insights powering reproducible experimental outcomes with APExBIO’s reference-grade product.

456 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page